Carbutamide

Carbutamide

SCHEMBL4078762

CCCCNC(=O)NS(=O)(=O)c1ccc(N)cc1.CCCCNC(=O)NS(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.76
TSHR P16473 3/20 0.76
CYP2C9 P11712 2/20 0.76
LMNA P02545 2/20 0.76
TDP1 Q9NUW8 2/20 0.76
ALB P02768 1/20 0.76
FBP1 P09467 6/20 0.69
SMN1; SMN2 Q16637 3/20 0.61
CYP3A4 P08684 1/20 0.61
THRB P10828 1/20 0.61
NFKB1 P19838 1/20 0.61
HTR2A P28223 1/20 0.61
CYP2C19 P33261 1/20 0.61
ADRA1A P35348 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
DHFR P00374 1/20 0.55
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbutamide SCHEMBL49231 1.00 ALDH1A1 (0.76) ALDH1A1TSHRCYP2C9LMNATDP1
Carbutamide SCHEMBL7615910 0.91 ALDH1A1 (0.78) ALDH1A1TSHRCYP2C9LMNATDP1
Tolbutamide SCHEMBL15918 0.87 ALDH1A1 (1.00) ALDH1A1TSHRCYP2C9LMNATDP1
Tolbutamide SCHEMBL1536920 0.87 ALDH1A1 (1.00) ALDH1A1TSHRCYP2C9LMNATDP1
SCHEMBL11390868 0.86 CYP2C9 (0.69) ALDH1A1TSHRCYP2C9LMNATDP1
Carbutamide SCHEMBL7833740 0.86 CYP2C9 (0.61) ALDH1A1TSHRCYP2C9LMNATDP1
Tolbutamide SCHEMBL7551276 0.85 ALDH1A1 (0.97) ALDH1A1TSHRCYP2C9LMNATDP1
Tolbutamide SCHEMBL11357518 0.85 ALDH1A1 (0.97) ALDH1A1TSHRCYP2C9LMNATDP1
Tolbutamide SCHEMBL140363 0.85 ALDH1A1 (0.97) ALDH1A1TSHRCYP2C9LMNATDP1
Tolbutamide SCHEMBL4367531 0.85 ALDH1A1 (0.97) ALDH1A1TSHRCYP2C9LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046341-B1 COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION Assistance Publique Hôpitaux De Paris (FR) 2016-07-13 EP disclosed
US-20130184293-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION UNIVERSITE PARIS DESCARTES (FR) 2013-07-18 US disclosed
US-8354452-B2 Compositions and methods for treating diabetes and neuropsychological dysfunction ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) 2013-01-15 US disclosed
US-20090306212-A1 Compositions and Methods for Treating Diabetes and Neuropsychological Dysfunction ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (FR) 2009-12-10 US disclosed
EP-2046341-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION Assistance Publique - Hopitaux de Paris (FR) 2009-04-15 EP disclosed
WO-2008015226-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) 2008-02-07 WO disclosed
EP-1884244-A1 Potassium channel ligands for treating diabetes and neuropsychological dysfunction Assistance Publique - Hopitaux de Paris (FR) 2008-02-06 EP disclosed